ClinicalTrials.gg
CompletedNCT03486938HOPE4MCIUpdated May 17, 2024Results posted

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

A Phase 2/3 interventional study of Placebo Oral Tablet and AGB101 220 mg tablet in Mild Cognitive Impairment and Prodromal Alzheimer's Disease, sponsored by AgeneBio. Completed at 24 sites in 2 countries. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by AgeneBio · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,421 studies in Cognitive Dysfunction with a site in United States — 329 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Enrollment
225th of 1,146
164 · median 59
Started
2018
with 83 others
Phase 2/3
12 of 1,421
1 open now
Registered
549th of 1,421
by date

Among the 1,421 studies in Cognitive Dysfunction with a site in United States, this one is the 225th largest by enrollment of the 1,146 interventional ones that give a count, is one of 84 that started in 2018, is one of 12 in phase 2/3, and was the 549th registered.

Cognitive Dysfunction

3,878 studies on the registry are indexed under Cognitive Dysfunction; 1,120 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

329 of the 1,421 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

324 more — sign in →

All 329 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 363 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 261 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,421 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) also known as prodromal AD. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ).

03

Conditions studied

  • Mild Cognitive Impairment
  • Prodromal Alzheimer's Disease
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects between 55 and 85 years old (inclusive) in good general health:

    1. Willing and able to consent and participate for the duration of the study
    2. Have eighth-grade education or good work history sufficient to exclude mental retardation
    3. Have visual and auditory acuity adequate for neuropsychological testing
    4. Have proficient fluency of the native local language to participate in all the neuropsychological test assessments
  2. Have a study partner who has sufficient contact with the subject to be able to provide assessment of memory changes, who can accompany the subject to all the clinic visits for the duration of each visit, and who is able to provide an independent evaluation of the subject's functioning
  3. Have MCI due to AD as defined by all of the following criteria and consistent with the National Institute on Aging-Alzheimer's Association criteria:

    1. scores between 24 and 30 (inclusive; exceptions may be made for subjects with \<8 years of education at the discretion of the sponsor)
    2. A memory complaint reported by the subject or his/her study partner
    3. Evidence of lower memory performance based on delayed recall in the International Shopping List Test (ISLT)
    4. A clinical dementia rating (CDR) score of 0.5 with a memory box score of ≥0.5
    5. Essentially preserved activities of daily living
    6. Cognitive decline not primarily caused by vascular, traumatic, or medical problems (alternative causes of cognitive decline are ruled out)
  4. Permitted medications:

    1. With potential pro-cognitive effects, such as cholinesterase inhibitors and memantine, must be at a stable dose for ≥3 months prior to screening and remain stable throughout the study; estrogen replacement therapy, Ginkgo biloba, and vitamin E must be at a stable dose for ≥4 weeks prior to screening and remain stable throughout the study
    2. Other psychotropics, such as antidepressants and antipsychotics, must be at a stable dose for ≥3 months prior to screening and remain stable throughout the study
  5. Willing and able to undergo imaging procedures:

    1. A Positron Emission Tomography (PET) scan with Florbetaben(an 18F isotope diagnostic agent) or documented evidence of an amyloid positive PET scan.

      The Florbetaben scan performed at baseline must be read by a qualified physician with experience in reading amyloid PET scans, and it should be consistent with the presence of amyloid plaques.

    2. Repeated MRI scans (3 Tesla) with no to MRI. MRI scan results are consistent with the diagnosis of amnestic MCI due to Alzheimer's disease with no findings of non-AD pathology that could account for the observed cognitive impairment.
  6. Willing to allow collection of blood for apolipoprotein E (ApoE) genotyping.

Exclusion criteria

Exclusion Criteria:

  1. Use of anticonvulsant medications or excluded psychotropic medications within 3 months prior to the baseline visit
  2. Participation in a therapeutic clinical study for any medical or psychiatric indications within 3 months (6 months for biologics) of the screening visit, or at any time during the study.

    Subjects must understand that they may only enroll in this clinical study once; they may not enroll in any other clinical study while participating in the current study, and they may not participate in a clinical study of a drug, biologic, therapeutic device, or medical food, in which the last dose/administration was received within 3 months (6 months for biologics) prior to screening.

  3. History of or lack of tolerability to AGB101 (levetiracetam)
  4. Severe renal impairment ( of \<30 mL/minute) or undergoing hemodialysis
  5. Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder (lifetime history; infant febrile seizures are not exclusionary), subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities
  6. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
  7. Diagnosis of major depression or bipolar disorder, as described in the , 5th Ed (DSM-5), within the past 3 years.

    Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol. Subjects must not have a major depressive disorder or other types of depression that could confound diagnosis of MCI due to AD, or clinical assessments, in the opinion of the investigator. The geriatric depression scale (long form score >9 suggests depression) results should be reviewed by the investigator to assist in this determination.

  8. Modified Hachinski Ischemic Scale (HIS) score >4
  9. History of schizophrenia (DSM-5 criteria)
  10. History of alcohol or substance abuse or dependence within the past 3 years (DSM-5 criteria)
  11. Any significant systemic illness or unstable medical condition that could lead to difficulty in complying with the protocol requirements.
  12. abnormalities in B12 or thyroid function test that might interfere with the study.

    A low B12 (below normative range for elderly) is exclusionary, unless follow-up labs (homocysteine and methylmalonic acid) indicate that it is not physiologically significant. If the B12 deficiency is treated, subjects may become eligible to participate in the study.

  13. Residence in a skilled nursing facility. Individuals in independent living communities, assisted living facilities, residential care facilities, or continuing care communities are eligible provided they engage in a sufficient spectrum of activity to permit assessment of all 6 domains contributing to the CDR-SB. Individuals in these facilities must also have a caregiver who has the ability to observe the subject during the study and can participate in clinical evaluations.
  14. Any use of excluded medications (e.g., antiepileptics, certain antidepressants or antipsychotics, antihistamines with anticholinergic properties, opiates)
  15. Participation in clinical studies using the ISLT, Behavioral Pattern Separation (BPS-O) task, or the trail making test (A, B) within 1 month of screening
  16. Female subjects must not be pregnant, lactating, or of (i.e., they must be 2 years post menopause or surgically sterile)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
164 participants (actual)

Study arms

  • Placebo comparator
    Placebo Oral Tablet

    Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.

    Drug: Placebo Oral Tablet

  • Experimental
    AGB101 220 mg tablet

    Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.

    Drug: AGB101 220 mg tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline

    CDR-SB scores at baseline were subtracted from CDR-SB scores at week 78 to generate the change score from baseline, with a possible total range of -18 to 18. Positive change scores reflect greater impairment on the CDR-SB at week 78, while negative change scores reflect less impairment on the CDR-SB at week 78.

    Time frame: 78 weeks

Secondary outcomes

  1. Change in Mini Mental Status Exam (MMSE) Score From Baseline

    MMSE scores at baseline were subtracted from MMSE scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect improved performance on the MMSE at week 78, while negative change scores reflect worsening performance on the MMSE at week 78.

    Time frame: 78 weeks

  2. Change in Functional Activities Questionnaire (FAQ) Score From Baseline

    FAQ scores at baseline were subtracted from FAQ scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect greater impairment on the FAQ at week 78, while negative change scores reflect less impairment on the FAQ at week 78.

    Time frame: 78 weeks

07

Results

Posted May 17, 2024

Participant flow

Participant flow — Overall Study
MilestonePlacebo Oral TabletAGB101 220 mg Tablet
Started8381
Completed6655
Not completed1726

Outcome measures

PrimaryChange in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline

CDR-SB scores at baseline were subtracted from CDR-SB scores at week 78 to generate the change score from baseline, with a possible total range of -18 to 18. Positive change scores reflect greater impairment on the CDR-SB at week 78, while negative change scores reflect less impairment on the CDR-SB at week 78.

Time frame:
78 weeks
Reported as:
Mean · score on a scale
Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline
score on a scalePlacebo Oral TabletAGB101 220 mg Tablet
Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline1.1 ± 2.9 ± 1.5
SecondaryChange in Mini Mental Status Exam (MMSE) Score From Baseline

MMSE scores at baseline were subtracted from MMSE scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect improved performance on the MMSE at week 78, while negative change scores reflect worsening performance on the MMSE at week 78.

Time frame:
78 weeks
Reported as:
Mean · units on a scale
Change in Mini Mental Status Exam (MMSE) Score From Baseline
units on a scalePlacebo Oral TabletAGB101 220 mg Tablet
Change in Mini Mental Status Exam (MMSE) Score From Baseline-1.9 ± 3.7-2.2 ± 2.8
SecondaryChange in Functional Activities Questionnaire (FAQ) Score From Baseline

FAQ scores at baseline were subtracted from FAQ scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect greater impairment on the FAQ at week 78, while negative change scores reflect less impairment on the FAQ at week 78.

Time frame:
78 weeks
Reported as:
Mean · units on a scale
Change in Functional Activities Questionnaire (FAQ) Score From Baseline
units on a scalePlacebo Oral TabletAGB101 220 mg Tablet
Change in Functional Activities Questionnaire (FAQ) Score From Baseline3.6 ± 6.44 ± 5.3

Adverse events

Collected over 18 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Oral Tablet0/83 (0%)10/83 (12%)49/83 (59%)
AGB101 220 mg Tablet2/78 (2.6%)13/78 (16.7%)40/78 (51.3%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPlacebo Oral TabletAGB101 220 mg Tablet
Sinus node dysfunctionCardiac disorders0/833/78
SeizureNervous system disorders1/832/78
Hip fractureInjury, poisoning and procedural complications2/830/78
Atrial fibrillationCardiac disorders0/831/78
Atrioventricular block second degreeCardiac disorders0/831/78
Coronary artery diseaseCardiac disorders0/831/78
AppendicitisInfections and infestations0/831/78
CystitisInfections and infestations0/831/78
HypoglycemiaMetabolism and nutrition disorders0/831/78
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/831/78
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlacebo Oral TabletAGB101 220 mg Tablet
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders20/8311/78
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications15/8312/78
Nervous system disordersNervous system disorders15/838/78
Psychiatric disordersPsychiatric disorders9/8314/78
Gastrointestinal disordersGastrointestinal disorders13/837/78
Infections and infestationsInfections and infestations13/8311/78
General disorders and administration site conditionGeneral disorders10/835/78
InvestigationsInvestigations8/837/78
Blood and lymphatic system disordersBlood and lymphatic system disorders7/832/78
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders7/832/78

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo Oral TabletAGB101 220 mg TabletTotal
Mean73.1 ± 772.2 ± 6.772.7 ± 6.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Oral TabletAGB101 220 mg TabletTotal
Female403272
Male434992
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Oral TabletAGB101 220 mg TabletTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American257
White8175156
More than one race000
Unknown or Not Reported000
Clinical Dementia Rating-Sum of Boxes (CDR-SB)
Clinical Dementia Rating-Sum of Boxes (CDR-SB)(units on a scale)Placebo Oral TabletAGB101 220 mg TabletTotal
Mean2.7 ± 1.12.7 ± 12.7 ± 1
Mini Mental Status Exam (MMSE)
Mini Mental Status Exam (MMSE)(units on a scale)Placebo Oral TabletAGB101 220 mg TabletTotal
Mean26 ± 2.226.2 ± 2.126.1 ± 2.1
Functional Activities Questionnaire (FAQ)
Functional Activities Questionnaire (FAQ)(units on a scale)Placebo Oral TabletAGB101 220 mg TabletTotal
Mean7.0 ± 5.27.6 ± 5.57.3 ± 5.4
08

Study locations

24 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • Senior Clinical Trials, Inc.
    Laguna Hills, California 92653, United States
  • Excell Research Inc
    Oceanside, California 92056, United States
  • The Mile High Research Center
    Denver, Colorado 80218, United States
  • Boynton Beach Medical Research Institite
    Boynton Beach, Florida 33437, United States
  • Brain Matters Research
    Delray Beach, Florida 33445, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Miami Jewish Health
    Miami, Florida 33137, United States
  • Bioclinica Research
    Orlando, Florida 32806, United States
  • IMIC Research
    Palmetto Bay, Florida 33157, United States
  • The Roskamp Institute, Inc
    Sarasota, Florida 34243, United States
  • Brain Matters Research
    Stuart, Florida 34997, United States
  • NeuroStudies.net, LLC
    Decatur, Georgia 30033, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21205, United States
  • Memory Center/Hattiesburg Clinic
    Hattiesburg, Mississippi 39401, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • The NeuroCognitive Institute
    Mount Arlington, New Jersey 07856, United States
  • Global Medical Institutes LLC; Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Neurology Specialist of Monmouth County, PA
    West Long Branch, New Jersey 07764, United States
  • Neurological Associates of Albany PC
    Albany, New York 12208, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Clinical Biotechnology Research Institute at RSFH
    Charleston, South Carolina 29401, United States
  • Toronto Memory Program
    Toronto, Ontario M3B 2S7, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Nov 2022, 46 months.

Results were first posted in May 2024, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2018
First posted
Apr 3, 2018
StartActual
Dec 13, 2018
Primary completionActual
Nov 2, 2022
CompletionActual
Nov 2, 2022
Results first posted
May 17, 2024
Last update
May 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03486938
Lead sponsor
AgeneBio
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
Dec 13, 2018
Primary completion
Nov 2, 2022
Completion
Nov 2, 2022
Results posted
May 17, 2024
Last update
May 17, 2024

Study contacts

Richard Mohs, PhD
principal investigator · AgeneBio
Sharon Rosenzweig-Lipson, PhD
study director · AgeneBio
Russell Barton, MS
study director · AgeneBio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion